顎関節症に対するＲＡＫ‐５９１（Ｅｔｏｄｏｌａｃ：ハイペン錠）の臨床的有効性および安全性に関する検討

DOI 被引用文献5件 参考文献18件

書誌事項

タイトル別名
  • Clinical study of RAK-591 (Etodolac, Hypen<SUP>®</SUP> tablet) in treatment of temporomandibular joint disorders

この論文をさがす

抄録

To evaluate the efficacy and safety of RAK-591 in the treatment of patients with temporomandibular joint disorders, RAK-591 was orally administered, at a dose of 200mg, twice daily, for 4 weeks. In a total of 101 subjects, the efficacy was evaluated in 86 cases, and safety in 90 cases. The improvement rate of pain on exercise (including “improved” or better) was 45.0% (36/80 cases) after 2 weeks, 50.0% (29/58 cases) after 4 weeks, and 57.0% (49/86 cases) at the end of medication (49 improved cases consisted of 16 completely improved cases at 2 weeks, and 33 improved-or-better-rated cases at 4 weeks). The pain on exercise on VAS was 51.8mm on average before administration, and 16.1mm on average at the end, showing a significant reduction (p<0.001). The maximal range of passive and pain-free opening expanded from 32.9mm, on average, before administration, to 41.4mm, on average, after 2 weeks, and 42.6mm, on average, at the end, indicating significant improvement (p<0.001). On the other hand, adverse reactions were observed in 17 of 90 cases (18.9%), but none were serious. The main adverse reactions were gastrointestinal symptoms, and these recovered after stopping the medication without any treatment.<BR>In conclusion, RAK-591 exhibited good clinical efficacy and high safety in the treatment of temporomandibular joint disorders, and it was considered to be a useful drug.

収録刊行物

被引用文献 (5)*注記

もっと見る

参考文献 (18)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ